Lutetium Lu 177 dotatate
Peptide receptor radionuclide therapy (PRRT); FDA-approved Jan 2018 for somatostatin receptor-positive GEP-NETs; first PRRT approved in the US.
Description
Lutetium Lu 177 dotatate is a research-grade compound offered by EuroAsia RND for laboratory research use only. Mechanism of action: SSTR-Targeted Peptide Receptor Radionuclide Therapy (Lu-177). Purity: ≥95% (radiochemical). Certificate of Analysis (CoA) and Safety Data Sheet (SDS) are available on request. Contact us for current pricing and availability.
Additional information
| Effect | SSTR-Targeted Peptide Receptor Radionuclide Therapy (Lu-177) |
|---|---|
| Purity | ≥95% (radiochemical) |
| Molecular Formula | C65H92LuN14O19 (complex) |
| CAS Number | 1397851-53-4 |
